Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
0.45 ^AUD	+16.88%		+25.00%	+30.43%

Apr. 18	Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	CI
Apr. 18	Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	MT

Immutep Limited Announces Change of Registered Office Address, Effective 15 December 2021

December 14, 2021 at 12:14 am EST

Immutep Limited announced that its registered office and principal place of business will change, with effect from 15 December 2021 to: Level 33, Australia Square, 264 George Street, Sydney, NSW 2000, Australia.

Latest news about Immutep Limited

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	Apr. 18	CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	Apr. 18	MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay	Apr. 17	MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial	Apr. 16	MT
Encouraging results for Immutep's cancer therapies	Mar. 25	FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti	Mar. 05	CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss	Feb. 27	MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer	Jan. 04	CI
Immutep Doses First Patient in Cancer Trial	Jan. 03	MT
Immutep Limited Announces Change of Registered Office Address	Dec. 21	CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Dec. 21	CI
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government	Dec. 07	MT
Immutep Secures 1.6 Million Euro French R&D Tax Rebate for 2022	Dec. 06	MT
Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment	Nov. 22	MT
Immutep Expands Sites for Phase 1 Cancer Trial	Nov. 22	MT
Immutep Limited Announces Completion of Patient Enrollment in the Tacti-003 (Keynote-Pnc-34) Phase Iib Trial	Nov. 09	CI
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	Nov. 09	CI
Immutep Completes Enrollment for Phase 2b Cancer Trial	Nov. 09	MT
Immutep Limited Announces Completion of the Safety Lead-In and Opening of the Randomized Phase Ii of the Aipac-003 Phase II/III Trial in Metastatic Breast Cancer	Nov. 06	CI
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer	Nov. 03	CI
Immutep Secures AU$1 Million Tax Rebate for Fiscal Year 2023	23-10-25	MT
Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023	23-10-24	CI
Immutep Says Efti Plus Keytruda Showed 'Excellent Overall Survival Benefit' in People With Lung Cancer	23-10-23	MT

Chart Immutep Limited

Duration

Period

More charts

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - European Society for Medical Oncology Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.45 AUD

Average target price

0.9 AUD

Spread / Average Target

+100.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUTEP LIMITED	+30.43%	297M
IQVIA HOLDINGS INC.	+4.01%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+8.99%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.94%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.63%	18.47B
MEDPACE HOLDINGS, INC.	+29.41%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.26%	12.33B
UNITED THERAPEUTICS CORPORATION	+9.27%	11.03B

Other Biotechnology & Medical Research